Fig. 7. JZL184 inhibits GSC self-renewal and tumorigenicity.

a, b Limiting dilution assays (LDAs) performed using 528 cells (B) and X01 cells (C) treated with JZL184 (1 μM). (n = 24). c H&E staining of the whole brain and immunohistochemical (IHC) analysis of MAGL and Iba-1 in a JZL184-treated orthotopic xenograft mouse model. Scale bar, 100 µm. The sample is extracted at 32 days after cell injection. d, e Representative IF images (d) and corresponding quantification (e) of PGE₂, CD86, CD206, ARG1, Nestin, and GFAP in a JZL184-treated orthotopic xenograft mouse model. Scale bar, 50 µm. All error bars represent mean ± SEM (n = 3). *P < 0.05, **P < 0.01, t-test. f Kaplan–Meier survival analysis of mice implanted with X01 cells treated with JZL184 or vehicle (n = 8; 2.5 × 10⁴ cells injected per mouse, log-rank test). Median survival of the mice treated with vehicle, or JZL184 was 36 days, and 40 days, respectively.